July 22, 2014
1 min read

Insignificant link found between genotype, response to AREDS supplements

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Genotype had an insignificant association with response to nutritional supplementation, according to study findings.

In a retrospective analysis of data from the first AREDS, researchers attempted to gauge whether genotypes at two major loci related to age-related macular degeneration — complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) — had any significant effect on the relative benefits of AREDS supplements in a subset of patients at high risk for progression to late AMD.

Patients were randomly assigned to one of four AREDS supplement treatment arms: placebo; vitamins C and E, and beta-carotene; zinc or antioxidant plus zinc.

Among the 1,237 patients analyzed, late AMD developed in 385 patients (31.1%). The CFH and ARMS2 genotypes were associated independently with development of late AMD (P = .005 and P < .0001, respectively).

Results showed that the combination of CFH, ARMS2 and treatment with the four different AREDS components produced no statistically significant interaction, according to the researchers.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.